News

IONTAS Antibody approved for first in patient use in the treatment of B cell Acute Lymphoblastic Leukemia

Cambridge, UK and Moscow, Russia, 09 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that IBC Generium, leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL).

This is the first IBC Generium drug candidate developed using IONTAS technology, which was approved for clinical trials. IBC Generium and IONTAS worked together to generate the anti-CD3 component of the bispecific molecule. This approval reflects on the quality of antibodies generated and expertise within IBC Generium to reach this important clinical milestone. Following on from this trial it is anticipated that further clinical trials incorporating IONTAS antibodies will be driven forward by clients of IONTAS in the coming few years.

Dr John McCafferty, CEO of IONTAS, said: “We are very proud of our involvement in this project and delighted that Generium have achieved this important landmark. We are hopeful for success in this initial trial and are excited by the prospect of our anti-CD3 antibody contributing more broadly to the armoury of new and innovative cancer treatments.”

Dr Ravil Khamitov, CEO of IBC Generium, said: “IONTAS was selected because of its robust track record and technical know-how. We were confident IONTAS would deliver antibodies suitable for use in our bispecific programs and were not disappointed. This trial is vindication of that confidence. We look forward to a successful clinical trial and further success with other antibodies developed with IONTAS.”

Dr Neil Butt, CBO and Dr John McCafferty, CEO and Founder of IONTAS, will attend JP Morgan (San Francisco, CA) from January 13 – 16 2020. Dr Neil Butt will be at Antibody Engineering and Therapeutics (San Diego, CA) from 9 – 13 December 2019.

For further information, please visit:

https://www.iontas.co.uk/technologies/

http://www.generium.ru/en/research/

ENDS

Notes to Editors

IONTAS Ltd

Neil Butt, Chief Business Officer

 

Tel: +44 1223 750801

bd@iontas.co.uk

Zyme Communications

Lorna Cuddon

 

Tel: +44 (0)1223 968 920

lorna.cuddon@zymecommunications.com

Generium Media Inquiries

 

Generium Investor Inquires

Vsevolod Letsko

Head, External Communications

pr@generium.ru

Tel: +7 (495) 988-47-94

 

Dmitriy Mamykin

Head, International Department

bd@generium.ru

Tel: +7 (495) 988-47-94

About IONTAS

IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS offers proprietary antibody discovery platforms including Mammalian Display where full length antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; IONTAS have also developed a novel “KnotBody” format which facilitates the targeting of antibodies to ion channels, GPCRs and proteases. www.iontas.co.uk

About Generium

Generium is the leading Russian biopharmaceutical company, focused on developing and commercializing diagnostic systems and pharmaceutical products for the treatment of orphan diseases, infection diseases, cancer, multiple sclerosis, myocardial infarction and strokes. Generium consists of a high-end R&D center and a fully integrated manufacturing plant. Generium has more than 30 innovative products in the pipeline, including enzymes, monoclonal antibodies and ATMPs. Generium is headquartered in Moscow, Russia. Additional information can be found at www.generium.ru/en.

Back to the list